<DOC>
	<DOCNO>NCT00793494</DOCNO>
	<brief_summary>The aim study determine efficacy administration Bifidobacterium bifidum R0071 , Bifidobacterium longum R0175 , Lactobacillus helveticus R0052 , Lactobacillus Delb . SSP bulgaricus R9001 , Lactobacillus rhamnosus R0011 , Lactococcus Lactis SSP . lactis R1058 et Streptococcus thermophilus ( Probaclacâ„¢ ) give twice day 4 week digestive symptom evaluate subjectively child age 8 18 year irritable bowel syndrome versus placebo . This study double-blind randomize control study . 84 child include . After inclusion , 15-day period observation precedes randomization Day 0 . Patients receive Probaclac placebo 4 week . At end treatment period , patient follow 2-week period follow-up . 4 visit 4 phone call plan study .</brief_summary>
	<brief_title>Efficacy Probaclac Irritable Bowel Syndrome Children Aged 8 18 Years</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Children 8 18 year Irritable bowel syndrome accord Rome III criterion Not able collaborate Known Digestive malformation History digestive surgery ( except hernia repair appendectomy ) History know digestive disease ( Crohn 's , ulcerative colitis , esophagitis , peptic ulcer , celiac disease ) Symptoms suggestive organic disease ( rectal bleeding , weight loss History chronic extradigestive disease Acute gastroenteritis th e4 week prior inclusion Central catheter , artificial cardiac valve , endocardiac prothesis Current Antidepressant treatment Patients take treatment irritable bowel syndrome unable cease current treatment Patient take regularly probiotic natural product</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Irritable bowel syndrome</keyword>
	<keyword>Children</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Probiotics</keyword>
</DOC>